[1]陈佳沁,黄颖,姚进.视网膜静脉阻塞继发黄斑水肿抗VEGF治疗后OCTA指标变化与基线房水细胞因子的相关性分析[J].眼科新进展,2024,44(7):536-539.[doi:10.13389/j.cnki.rao.2024.0103]
 CHEN Jiaqin,HUANG Ying,YAO Jin.Correlation between baseline aqueous humor cytokines and optical coherence tomography angiography changes after anti-vascular endothelial growth factor treatment for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2024,44(7):536-539.[doi:10.13389/j.cnki.rao.2024.0103]
点击复制

视网膜静脉阻塞继发黄斑水肿抗VEGF治疗后OCTA指标变化与基线房水细胞因子的相关性分析/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
44卷
期数:
2024年7期
页码:
536-539
栏目:
应用研究
出版日期:
2024-07-01

文章信息/Info

Title:
Correlation between baseline aqueous humor cytokines and optical coherence tomography angiography changes after anti-vascular endothelial growth factor treatment for macular edema secondary to retinal vein occlusion
作者:
陈佳沁黄颖姚进
210000 江苏省南京市,南京医科大学眼科医院
Author(s):
CHEN JiaqinHUANG YingYAO Jin
the Affiliated Eye Hospital of Nanjing Medical University,Nanjing 210000,Jiangsu Province,China
关键词:
视网膜静脉阻塞黄斑水肿细胞因子黄斑中心凹无血管区
Keywords:
retinal vein occlusion macular edema cytokines fovea avascular zone
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2024.0103
文献标志码:
A
摘要:
目的 探讨视网膜静脉阻塞继发黄斑水肿(RVO-ME)患者抗血管内皮生长因子(VEGF)治疗后光学相干断层扫描血管成像(OCTA)指标变化与基线房水细胞因子的关系。
方法 纳入2021年10月至2023年1月在南京医科大学眼科医院确诊为RVO-ME的患者30例30眼,均采用3+PRN方案的玻璃体内注射抗VEGF药物。分别收集第1次和第3次注射前的房水,采用Luminex液相芯片技术测定VEGF、白细胞介素(IL)、γ-干扰素(IFN-γ)、细胞间黏附分子-1(ICAM-1)和血小板源性生长因子(PDGF)等细胞因子的表达水平。利用OCTA测量黄斑中心凹视网膜厚度(CMT)、黄斑中心凹无血管区(FAZ)面积、周长(PERIM)、非圆度指数(AI)、FAZ范围300 μm宽度内的血管密度(FD-300)。采用国际标准对数视力表检查最佳矫正视力(BCVA),并换算为最小分辨角对数(logMAR)视力。比较RVO-ME患者抗VEGF治疗前后房水中细胞因子表达水平和OCTA指标的变化,分析治疗后OCTA指标变化与基线房水细胞因子的关系。
结果 RVO-ME患者患眼治疗后房水细胞因子中VEGF、ICAM-1、PDGF、IL-8、IL-10表达水平均下降,差异均有统计学意义(均为P<0.05);治疗后BCVA改善(P<0.001),CMT、AI及FD-300指标均下降,差异均有统计学意义(均为P<0.05)。相关性分析结果显示,基线IL-13水平与AI变化值呈负相关(r=-0.388,P<0.05);基线IL-8水平与FD-300变化值呈负相关(r=-0.421,P<0.05)。
结论 基线房水细胞因子IL-13和IL-8可能与RVO-ME患眼抗VEGF治疗后视网膜黄斑区微血管结构改善程度有关。针对RVO-ME的治疗与管理不应局限于抗血管治疗,还应针对性进行抗炎治疗。
Abstract:
Objective To investigate the relationship between baseline aqueous humor cytokines and optical coherence tomography angiography (OCTA) changes in eyes with macular edema secondary to retinal vein occlusion (RVO-ME) after anti-vascular endothelial growth factor (VEGF) treatment.
Methods From October 2021 to January 2023, 30 eyes of 30 patients diagnosed with RVO-ME at the Affiliated Eye Hospital of Nanjing Medical University were included in this study. All eyes were treated with the intravitreal injection of anti-VEGF drugs once a month for 3 consecutive months and then treated as needed. The aqueous humors before the first and third injections were collected. The expression levels of VEGF, interleukins (IL), γ-interferon (IFN-γ), intercellular adhesion molecule-1 (ICAM-1), and platelet-derived growth factor (PDGF) were detected using the Luminex platform. The central macular thickness (CMT), fovea avascular zone (FAZ) area, perimeter (PERIM), acircularity index (AI), and the vessel density in a 300 μm wide region around FAZ (FD-300) were measured using OCTA. The best corrected visual acuity (BCVA) was examined using the international standard logarithmic visual acuity chart, which was converted into the logarithm of the minimum angle of resolution (logMAR) for statistics. Aqueous humor cytokines and OCTA parameters were compared before and after anti-VEGF treatment for RVO-ME, and the relationship between OCTA changes (the difference between before and after treatment) and baseline aqueous humor cytokines was analyzed.
Results After treatment, the levels of VEGF, ICAM-1, PDGF, IL-8, and IL-10 in RVO-ME patients decreased (all P<0.05), the BCVA improved (P<0.001), and CMT, AI and FD-300 decreased (all P<0.05). Correlation analysis results showed that baseline IL-13 was negatively correlated with the AI change (r=-0.388, P<0.05), and baseline IL-8 was negatively correlated with the FD-300 change (r=-0.421, P<0.05).
Conclusion Baseline IL-13 and IL-8 may be related to the improvement of the retinal macular microvascular structure after anti-VEGF treatment for RVO-ME. For the treatment and management of RVO-ME, in addition to anti-VEGF therapy, targeted anti-inflammatory therapy should also be considered.

参考文献/References:

[1] ROMANO F,LAMANNA F,GABRIELLE P H,TEO K Y C,BATTAGLIA PARODI M,IACONO P,et al.Update on retinal vein occlusion[J].Asia Pac J Ophthalmol,2023,12(2):196-210.
[2] WONS J,PFAU M,WIRTH M A,FREIBERG F J,BECKER M D,MICHELS S.Optical coherence tomography angiography of the foveal avascular zone in retinal vein occlusion[J].Ophthalmologica,2016,235(4):195-202.
[3] WANG B,ZHANG X,CHEN H,KOH A,ZHAO C,CHEN Y.A review of intraocular biomolecules in retinal vein occlusion:toward potential biomarkers for companion diagnostics[J].Front Pharmacol,2022,13:859951.
[4] QIN H F,SHI F J,ZHANG C Y,LUO D W,QIN S Y,WU J,et al.Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion[J].Int J Ophthalmol,2022,15(8):1296-1304.
[5] KANG J W,YOO R,JO Y H,KIM H C.Correlation of microvascular structures on optical coherence tomography angiography with visual acuity in retinal vein occlusion[J].Retina,2017,37(9):1700-1709.
[6] 李泽锋,周希瑗,刘丹宁,周家林,马宁.视网膜中央静脉阻塞黄斑区微血管结构特征性改变[J].中华实验眼科杂志,2022,40(7):664-669.
LI Z F,ZHOU X Y,LIU D N,ZHOU J L,MA N.Characteristic changes of macular microvascular structure in central retinal vein occlusion[J].Chin J Exp Ophthalmol,2022,40(7):664-669.
[7] GONG D,YU W,ZHANG X,YANG Z,ZOU X,QU Y,et al.A morphological study of the foveal avascular zone in patients with diabetes mellitus using optical coherence tomography angiography[J].Graefes Arch Clin Exp Ophthalmol,2016,254(5):873-879.
[8] 杨治坤,于伟泓,陈有信.视网膜分支静脉阻塞继发黄斑水肿患眼玻璃体腔注射康柏西普治疗后黄斑区微血管结构改变[J].中华眼底病杂志,2021,37(9):675-680.
YANG Z K,YU W H,CHEN Y X.Microvascular changes of macular edema secondary to branch retinal vein occlusion treated with intravitreal conbercept injection[J].Chin J Ocul Fundus Dis,2021,37(9):675-680.
[9] SHCHUKO A G,ZLOBIN I V,IUREVA T N,OSTANIN A A,CHERNYKH E R,MIKHALEVICH I M.Intraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy[J].Indian J Ophthalmol,2015,63(12):905-911.
[10] NOMA H,MIMURA T,YASUDA K,SHIMURA M.Cytokine kinetics after monthly intravitreal bevacizumab for retinal vein occlusion associated with macular oedema[J].Ophthalmic Res,2016,56(4):207-214.
[11] QI H,DONG L,FANG D,CHEN L,WANG Y,FAN N,et al.A novel role of IL13Rα2 in the pathogenesis of proliferative vitreoretinopathy[J].Front Med,2022,9:831436.
[12] ZHANG J,ZHANG J,ZHANG C,ZHANG J,GU L,LUO D,et al.Diabetic macular edema:current understanding,molecular mechanisms and therapeutic implications[J].Cells,2022,11(21):3362.
[13] LEE W J,KANG M H,SEONG M,CHO H Y.Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion[J].Br J Ophthalmol,2012,96(11):1426-1430.
[14] FUKAMI M,IWASE T,YAMAMOTO K,KANEKO H,YASUDA S,TERASAKI H.Changes in retinal microcirculation after intravitreal ranibizumab injection in eyes with macular edema secondary to branch retinal vein occlusion[J].Invest Ophthalmol Vis Sci,2017,58(2):1246-1255.
[15] DENG Y,CAI X,ZHANG S,SU L,CHEN H,LIN Y,et al.Quantitative analysis of retinal microvascular changes after conbercept therapy in branch retinal vein occlusion using optical coherence tomography angiography[J].Ophthalmologica,2019,242(2):69-80.

相似文献/References:

[1]王刚.曲安奈德联合氪激光治疗视网膜静脉阻塞的临床疗效观察[J].眼科新进展,2013,33(7):000.
[2]马宇 刘意 郭娟 周利晓.金纳多联合血栓通对视网膜静脉阻塞患者同型半胱氨酸水平的影响[J].眼科新进展,2013,33(9):000.
[3]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[4]袁子茗 王帅 宋蓓雯 胡健艳 吴强.维速达尔光动力疗法诱导兔视网膜静脉阻塞的实验研究[J].眼科新进展,2012,32(9):000.
[5]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[6]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[7]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[8]李娟娟 李燕.先天性及获得性视盘血管袢的临床观察[J].眼科新进展,2013,33(11):000.
[9]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[10]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[11]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[12]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗(Ranibizumab)治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[13]周洁,王宏彬,王文亭.雷珠单抗治疗视网膜静脉阻塞的临床研究[J].眼科新进展,2016,36(1):070.[doi:10.13389/j.cnki.rao.2016.0020]
 ZHOU Jie,WANG Hong-Bin,WANG Wen-Ting.Efficacy of intravitreal injection of ranibizumab for retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(7):070.[doi:10.13389/j.cnki.rao.2016.0020]
[14]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
 WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(7):471.[doi:10.13389/j.cnki.rao.2016.0126]
[15]张敏,朱健华,冯浩,等.视网膜静脉阻塞合并黄斑水肿患者黄斑区微结构改变与视力的相关性分析[J].眼科新进展,2016,36(11):1061.[doi:10.13389/j.cnki.rao.2016.0283]
 ZHANG Min,ZHU Jian-Hua,FENG Hao,et al.Macular microstructure changes in retinal vein occlusion and its correlation with visual acuity[J].Recent Advances in Ophthalmology,2016,36(7):1061.[doi:10.13389/j.cnki.rao.2016.0283]
[16]夏松,陈有信.视网膜静脉阻塞继发黄斑水肿的抗VEGF药物治疗进展[J].眼科新进展,2016,36(11):1093.[doi:10.13389/j.cnki.rao.2016.0292]
 XIA Song,CHEN You-Xin.Research progress on anti-VEGF drugs for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(7):1093.[doi:10.13389/j.cnki.rao.2016.0292]
[17]马为梅,雷晓琴,田芳,等.视网膜静脉阻塞黄斑水肿的多焦视网膜电图与光学相干断层扫描分析[J].眼科新进展,2017,37(7):651.[doi:10.13389/j.cnki.rao.2017.0165]
 MA Wei-Mei,LEI Xiao-Qin,TIAN Fang,et al.Multifocal electroretinogram and optical coherence tomography characteristics of macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(7):651.[doi:10.13389/j.cnki.rao.2017.0165]
[18]李筱荣,周怀蔚.重视黄斑水肿的病因、治疗及预防[J].眼科新进展,2019,39(7):601.[doi:10.13389/j.cnki.rao.2019.0139]
 LI Xiao-Rong,ZHOU Huai-Yu.Special attention to the cause,treatment and prevention of macular edema[J].Recent Advances in Ophthalmology,2019,39(7):601.[doi:10.13389/j.cnki.rao.2019.0139]
[19]梁婉玲,周怀胜,马海智,等.地塞米松玻璃体内植入剂Ozurdex治疗视网膜静脉阻塞继发黄斑水肿的短期疗效[J].眼科新进展,2019,39(7):666.[doi:10.13389/j.cnki.rao.2019.0153]
 LIANG Wan-Ling,ZHOU Huai-Sheng,MA Hai-Zhi,et al.The short-term efficacy of Ozurdex for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(7):666.[doi:10.13389/j.cnki.rao.2019.0153]
[20]栗怡然,朱瑞琳,杨柳.炎症在视网膜静脉阻塞性黄斑水肿中的作用[J].眼科新进展,2020,40(1):090.[doi:10.13389/j.cnki.rao.2020.0023]
 LI Yiran,ZHU Ruilin,YANG Liu.Role of inflammation in macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2020,40(7):090.[doi:10.13389/j.cnki.rao.2020.0023]

备注/Memo

备注/Memo:
国家自然科学基金资助(编号:82271107)
更新日期/Last Update: 2024-07-05